title: Macular choroidal thickness and volume in eyes with angioid streaks measured by swept source optical coherence tomography.
abstract: OBJECTIVE
  To study the mean choroidal thickness and volume of the macula in eyes with angioid streaks using swept source optical coherence tomography (OCT) in the 1050-nm wavelength range.
  
  
  METHODS
  Prospective case series.
  
  
  METHODS
  The macular area of 39 eyes of 23 patients with angioid streaks and of 20 normal eyes of 20 matched controls (Group 1) was studied with a swept source OCT prototype system. Eyes with angioid streaks were classified into 1 of 4 groups: those without choroidal neovascularization (CNV) (Group 2); those with CNV that had no history of treatment (Group 3); those with CNV that had previously received only anti-vascular endothelial growth factor treatments (Group 4); and those with CNV that had previously received photodynamic therapy (Group 5). Using a raster scan protocol with 512 × 128 A-scans, we produced a macular choroidal thickness map (6 × 6 mm(2)).
  
  
  RESULTS
  There were no significant differences in age, axial length, or refractive error among the 5 groups. Mean choroidal thickness of the macula in Group 2 (218.9 ± 46.8 μm) was as great as that in Group 1 (218.8 ± 69.2 μm). However, the macular choroidal thickness in Group 3 (119.7 ± 49.2 μm), Group 4 (140.1 ± 64.9 μm), and Group 5 (144.0 ± 52.6 μm) was significantly less than that of Group 1 (P < .05). There were no statistical differences between Groups 3 through 5. In each group, the choroid of the nasal quadrant was significantly thinner compared to that in other quadrants (P < .05).
  
  
  CONCLUSIONS
  The choroid in eyes with angioid streaks without CNV was as thick as that in normal controls, but was significantly thinner in eyes with angioid streaks that had developed CNV.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: Abdallah A
authors.initials: AA
authors.lastname: Ellabban
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Akiko
authors.initials: A
authors.lastname: Matsumoto
authors.forename: Ken
authors.initials: K
authors.lastname: Ogino
authors.forename: Masanori
authors.initials: M
authors.lastname: Hangai
authors.forename: Sotaro
authors.initials: S
authors.lastname: Ooto
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamashiro
authors.forename: Masahiro
authors.initials: M
authors.lastname: Akiba
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000793:Angioid Streaks / Q000175:diagnosis* / Q000188:drug therapy; D058452:Axial Length, Eye; D002829:Choroid / Q000473:pathology*; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D010778:Photochemotherapy; D011446:Prospective Studies; D041623:Tomography, Optical Coherence
chemical_list: D020533:Angiogenesis Inhibitors; D004396:Coloring Agents; D007208:Indocyanine Green